The deal with U.S. biotech Septerna will see the companies develop pills to treat obesity, type 2 diabetes and other ...

Novo Nordisk has struck a collaboration and licensing deal with U.S. biotech Septerna to develop oral small molecule ...

Cuban annual raw sugar production will fall below 200,000 metric tons in 2025 for the first time since the 19th century, ...

Novo Nordisk inked an obesity deal worth up to $2.2 billion on Wednesday, sending shares of small biotech company Septerna into the stratosphere.Under the deal's terms, Novo and Septerna will ...

Novo Nordisk is partnering with the biotech Septerna to develop oral obesity drugs, as it aims for more convenient weight ...

It seems Novo Nordisk is leaving no stone unturned as it builds a pipeline of drug candidates for obesity and cardiometabolic ...

Vikrant Shrotriya said Human Mixtard is not being discontinued in India and will be supplied in vial presentation ...

Novo Nordisk partners with U.S. biotech Septerna in a $2.2 billion deal to develop oral small molecule drugs for obesity and ...

Novo Nordisk is making yet another bet on obesity, offering Septerna more than $200 million in upfront and near-term payments ...

Found, the leading specialized weight care telehealth platform developed by obesity specialists, today announced it will offer Wegovy® at $499 per month and Zepbound™ vials ranging from $349 to $699.